argenx in Bel20

argenx in Bel20

argenx, dat nog maar sinds 10 juli 2014 op de beurs noteert, krijgt op 18 juni een zitje in de Bel20-index. Argenx neemt de plaats in van het overgenomen Ablynx.

argenx selected for BEL 20 Index

June 05, 2018

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Euronext has selected argenx SE for inclusion in the BEL 20® Index on Euronext Brussels, effective June 18, 2018.

The BEL 20 Index represents the 20 largest companies traded on Euronext Brussels, subject to meeting Euronext Index Family criteria and review.  For a complete overview of criteria and index rules, please see The Index Family Rulebook, at www.euronext.com.

"We are proud to be the fourth biotech company included in the BEL 20 Index, a clear indicator of the growing importance of the sector for the Belgian economy,” commented Tim Van Hauwermeiren, CEO and co-founder of argenx. “We feel this inclusion also reflects our sustained growth as a company from our inception in 2008, through two public listings on Euronext Brussels and NASDAQ, into a world-class biotech company. To be listed among the largest public companies in Belgium is an honor and hopefully inspires a new generation of biotech entrepreneurs."

 

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. 

www.argenx.com    


For further information, please contact:

Joke Comijn, Director Corporate Communications & Investor Relations (EU)

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com